Showing 117 of 117on this page. Filters & sort apply to loaded results; URL updates for sharing.117 of 117 on this page
Recursion CEO on $688M Exscientia acquisition: Hope to bring better ...
AI Driving Innovation: Insights From Exscientia CEO Andrew Hopkins ...
Recursion acquires Exscientia | Amandeep Singh, Ph.D. posted on the ...
Recursion to merge with Exscientia - Silicon Canals
Congrats to both Recursion and Exscientia on their new partnership to ...
Exscientia CEO explains how AI is transforming drug discovery ...
Recursion Pharmaceuticals (RXRX) to Merge with Exscientia (EXAI)
Should Recursion and Exscientia Focus on Drug Discovery Services or ...
Recursion and Exscientia Enter Definitive Agreement to Create a Global ...
Exscientia and Recursion join forces | Dave H. posted on the topic ...
AI biotechs Recursion and Exscientia first held deal talks in 2022 ...
Recursion and Exscientia to Merge, Forming a Biotech Powerhouse Focused ...
Recursion and Exscientia sign deal for better medicines | Recursion ...
Oxford’s Exscientia sells to US firm Recursion for $688m | Insider Media
Exscientia and Recursion Enter Definitive Agreement - TOSP
Recursion acquires Exscientia for $688m | MergerLinks posted on the ...
Salt Lake's Recursion Pharmaceuticals merges with UK's Exscientia
Change at the top of Recursion as co-founder leaves CEO role | pharmaphorum
After a tough year, Exscientia folds into Recursion
Exscientia and Recursion merger approved by shareholders. 🚀 $EXAI $RXRX ...
Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in ...
Confirmatory Employment Letter Agreement between Exscientia | RECURSION ...
Recursion and Exscientia merge for rare diseases | Jakub (Kuba) Majcher ...
Some Thoughts on Recursion Acquisition of Exscientia | Jesse Harris ...
AI biotechs Exscientia and Recursion agree $688m merger | pharmaphorum
Recursion acquired Exscientia for $688 million to form AI drug ...
Recursion and Exscientia Merger Create A New AI Drug Discovery Leader ...
Recursion CEO Chris Gibson Steps Down After 12 Years of Leadership
Recursion acquires Exscientia for $688M | Cellular Intelligence posted ...
Exscientia y Recursion se fusionan: 778 millones de euros en efectivo y ...
Exscientia Focus Firmly On Pipeline After CEO Exit Scandal
Updated: Exscientia CEO brought down by allegations of inappropriate ...
Exscientia Fires CEO for “Inappropriate” Relationships with Two ...
Exscientia 2022-11 CEO at Evercore - EXAI - YouTube
Recursion to absorb Exscientia in ‘techbio’ deal | BioPharma Dive
AI biotech Recursion cuts jobs after Exscientia merger | STAT
Exscientia Dismisses CEO Andrew Hopkins Over Inappropriate Relationships
AI Drug Discovery Space Leaders Recursion And Exscientia Officially Combine
Recursion and Exscientia merge in AI deal | LucidQuest posted on the ...
Recursion CEO Chris Gibson out as company head after 12 years ...
Exscientia Fires CEO for "Inappropriate" Relationships with Two Employees
Recursion and Exscientia Shareholders Approve the Proposed
Recursion Completes Exscientia Merger, Creates AI Drug Discovery ...
Recursion CEO Chris Gibson out after 12 years | STAT
Ex-Allergan CEO Saunders pops up again in ‘blank cheque’ company ...
Exscientia, Nvidia Ortağı Recursion Pharmaceuticals ile Birleşiyor - Midas
Recently, a headline about Recursion caught my eye: “Recursion, the AI ...
Exscientia fires CEO—Chutes & Ladders
Alex Zhavoronkov on LinkedIn: Huge news today - Exscientia and ...
Recursion’s Ambitions: Developing 100+ Candidates, Joining with Exscientia
Exscientia announces multi-target, AI-driven drug discovery ...
HAYA Therapeutics Appoints Former Exscientia Executive Dr. Richard Law ...
Recursion Announces Promising Clinical Data on Lead AI-Based Drug ...
Exscientia on LinkedIn: #techbio #ai #drugdiscovery #pharma
Recursion and Exscientia, two leaders in the AI drug discovery space ...
Recursion’s CEO Discusses Pipeline Growth, Approach to AI and ML
AI drug developers Recursion, Exscientia to merge
Analysis of Exscientia’s Acquisition by Recursion
British A.I. drug discovery startup Exscientia buys Austrian cancer ...
Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Points ...
Chris Gibson on LinkedIn: Great to see Dave H. of Exscientia and Najat ...
Exscientia's CEO shares a pipeline overview and learnings from being ...
Exscientia on LinkedIn: Learn More About AI in Drug Discovery and ...
Exscientia Accelerates COVID-19 Drug Discovery Using AI | Business Wire
CEO Andrew Hopkins on Exscientia’s AI-Driven Approach to Modern Drug ...
Recursion and Exscientia, two leaders in the AI drug
A New Chapter in AI-Driven Drug Discovery as Recursion Completes ...
#techbio #recursion #ai #clinicaltrial #cancer | Exscientia
Exscientia - Presentations | Exscientia
Exscientia Uses Generative AI to Reimagine Drug Discovery
Founder Stories: Andrew Hopkins, Founder and CEO of Exscientia: Using ...
Dundee-founded Exscientia in billion-dollar merger
Robotics AI described Exscientia drug discovery methodology
Exscientia | AI Drug Discovery | Pharmatech
Exscientia Appoints John P. Overington, Ph.D., CTO; Maria-Louise ...
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery ...
BMS buys into AI-designed immune drug from Exscientia | pharmaphorum
Recursion ו- Exscientia, שתי מובילות בתחום גילוי התרופות בתחום הבינה ...
Samenvatting: Exscientia presenteert nieuwe preklinische gegevens voor ...
Recursion, Exscientia, and AI drug discovery’s moment of truth ...
Inside the Recursion-Exscientia definitive agreement - YouTube
recursion-exscientia-logo-1000x600.webp
Recursion's (formerly Exscientia) Cutting-Edge Lab Automation | HighRes ...
Recursion-Exscientia merger consolidates AI in drug discovery field ...
#recursion #exscientia #aiinhealthcare #drugdiscovery # ...
大型M&A・統合再編：RecursionとExscientiaの先にあるAI創薬の業界地図｜Pharma Insight Lab
On the Recursion-Exscientia Tie-Up | Mason Victors
Dylan Jovine | EXPLAINED: Recursion’s (RXRX) Recent Acquisition of ...
On Recursion–Exscientia and The Long Game of Reinventing Drug Discovery ...
Exscientia’s Chief AI Officer appointed Executive Chair, EPSRC (UKRI)
'We look like what the future of all biopharma companies will look like ...
Exscientia: a clinical pipeline for AI-designed drug candidates – UKRI
Recursion、CEO交代を発表：共同創業者クリス・ギブソン氏が会長に、ナジャット・カーン氏が新CEOに就任 – ニュース – 診療報酬 ...
“Bigger than DNA” — how AI is transforming the pharma industry | Sifted
Biotech Archives - Longevity.Technology - Latest News, Opinions ...
